131 related articles for article (PubMed ID: 38244800)
1. Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database.
Li J; Zelmat Y; Storck W; Laforgue EJ; Yrondi A; Balcerac A; Sommet A; Montastruc F
J Affect Disord; 2024 Apr; 350():452-467. PubMed ID: 38244800
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database.
de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL
Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063
[TBL] [Abstract][Full Text] [Related]
3. Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®).
Batteux B; Bennis Y; Bodeau S; Masmoudi K; Hurtel-Lemaire AS; Kamel S; Gras-Champel V; Liabeuf S
Bone; 2021 Dec; 153():116137. PubMed ID: 34343739
[TBL] [Abstract][Full Text] [Related]
4. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
[TBL] [Abstract][Full Text] [Related]
5. Statin-induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.
Gras-Champel V; Batteux B; Masmoudi K; Liabeuf S
Muscle Nerve; 2019 Oct; 60(4):382-386. PubMed ID: 31298743
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced vitiligo: a case/non-case study in Vigibase
Anthony N; Bourneau-Martin D; Ghamrawi S; Lagarce L; Babin M; Briet M
Fundam Clin Pharmacol; 2020 Dec; 34(6):736-742. PubMed ID: 32246859
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced tics: An observational postmarketing study.
Touafchia D; Montastruc F; Lapeyre-Mestre M; Rousseau V; Chebane L; Revet A
Hum Psychopharmacol; 2020 Jul; 35(4):e2734. PubMed ID: 32352603
[TBL] [Abstract][Full Text] [Related]
8. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.
Storck W; de Laportalière TT; Yrondi A; Javelot H; Berna F; Montastruc F
Psychopharmacology (Berl); 2024 Jun; 241(6):1205-1212. PubMed ID: 38376511
[TBL] [Abstract][Full Text] [Related]
9. Thirst and drugs: A study in the World Health Organization's pharmacovigilance database.
Montastruc JL
Br J Clin Pharmacol; 2024 Jun; 90(6):1525-1528. PubMed ID: 38627211
[TBL] [Abstract][Full Text] [Related]
10. Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database.
Dumont A; Dolladille C; de Boysson H; Alexandre J; Nguyen A; Deshayes S; Aouba A
Autoimmun Rev; 2022 Sep; 21(9):103157. PubMed ID: 35902047
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced Depression: a Case/Non Case Study in the French Pharmacovigilance Database.
Lafay-Chebassier C; Chavant F; Favrelière S; Pizzoglio V; Pérault-Pochat MC;
Therapie; 2015; 70(5):425-32. PubMed ID: 26056040
[TBL] [Abstract][Full Text] [Related]
12. Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis.
Hlavaty A; Roustit M; Montani D; Chaumais MC; Guignabert C; Humbert M; Cracowski JL; Khouri C
Br J Clin Pharmacol; 2022 Dec; 88(12):5227-5237. PubMed ID: 35679331
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors and Venous Thromboembolism: An Analysis of the WHO Pharmacovigilance Database.
Allouchery M; Beuvon C; Pérault-Pochat MC; Roblot P; Puyade M; Martin M
Clin Pharmacol Ther; 2022 Jul; 112(1):164-170. PubMed ID: 35426120
[TBL] [Abstract][Full Text] [Related]
14. Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies.
Cepaityte D; Siafis S; Papazisis G
Behav Brain Res; 2021 Apr; 404():113168. PubMed ID: 33581145
[TBL] [Abstract][Full Text] [Related]
15. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD; Marchese M; Cone EB; Paciotti M; Basaria S; Bhojani N; Trinh QD
JAMA Dermatol; 2021 Jan; 157(1):35-42. PubMed ID: 33175100
[TBL] [Abstract][Full Text] [Related]
16. Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database.
Mettler C; Monnet D; Kramkimel N; Tréluyer JM; Mouthon L; Brézin A; Dupin N; Valnet-Rabier MB; Chouchana L; Terrier B
Ophthalmology; 2021 Dec; 128(12):1748-1755. PubMed ID: 34000304
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
[TBL] [Abstract][Full Text] [Related]
18. Tramadol-induced hiccups: a case-noncase study in the European pharmacovigilance database.
García M; Lertxundi U; Aguirre C
Ther Adv Drug Saf; 2021; 12():20420986211021230. PubMed ID: 34211690
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization's database.
Bonaldo G; Vaccheri A; Melis M; Motola D
J Thromb Thrombolysis; 2020 Nov; 50(4):763-771. PubMed ID: 32445062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
